Eli Lilly Q3 earnings expected to beat Wall Street expectations
In This Article:
Eli Lilly (LLY) is expected to easily beat Wall Street's expectations when it reports third quarter earnings Wednesday morning before the bell, especially for its blockbuster weight-loss drug Zepbound. The GLP-1 drug continues to be a focal point of the company's near-term outlook.
Eli Lilly is expected to report $12.17 billion in revenue for the quarter and adjusted earnings per share of $1.51, according to Bloomberg consensus estimates.
Mizuho's healthcare expert Jared Holz wrote in a note to clients today that sales for Zepbound are estimated at $1.7 billion, while diabetes drug Mounjaro could slightly miss estimates of $3.8 billion as more patients turn to Zepbound for its higher-dosage weight-loss benefit.
And that tracks what investors are watching, Holz said.
"Some have asserted that the stock and group have peaked," he wrote. "Given the complexities around much of the Healthcare sector and difficulty establishing a simple thesis for the vast majority of names in Pharma/Biotech or otherwise, we think investors will remain very engaged in weight-loss names."
Lilly posted $4.3 billion in revenue last quarter from the two drugs.
Eli Lilly and Company (LLY)
最新報道
- 08-10據報SK海力士擬推706億美元
- 08-10據報阿里(09988.HK)整合內部
- 08-10阿里雲企業級智能分析產品Qu
- 08-10百度搭子連續推出生產力套件
- 06-26AI搶走記憶體！繼蘋果後 微軟
- 06-26蘋果漲價凸顯通膨難降 降息
- 06-02美伊互相打擊升級；英偉達推出
- 04-22小米 REDMI 春季雙新品！K Pad
- 04-01個人訊息｜Perplexity 用戶提
- 01-27Kirin 9030 系列產能穩定爬